You would have to assume the product would first b
Post# of 9122
They could monitor quality and more importantly work out any kinks. Would you agree?
It would also serve as a proof source of the product in action.
There is still pending test data from U.S. federal agency and large medical device company. I see this as a catalyst in itself.
It's refreshing to hear the word investors. If they turn out to be big time investors, this would also be a catalyst.
Looks like their will be plenty of news coming in the next few months and I expect good price momemtum from here.
I rate this as a strong buy. Its only 17 cents.